4DMT’s 4D-150 Moves Into Phase 3 for DME, Intensifying Pressure on Ocular’s AXPAXLI

4D-150 is now in Phase 3 for DME after two-year SPECTRA data showed durable vision gains and fewer injections, expanding the race with implants like AXPAXLI.